Member Info for sir_digby

Well this will cheer everyone up:

ONT (oxford nanopore) a gnats arse away from 5bn mcap this morning. While we trade at cash and inventory + 50m (which encompasses the 10m we paid for IT/IS and H2 earnings). Effing dispute, if you didn't laugh you'd cry.

Let the DHSC know, they're always up for a freebie.

Nobody will want this litigated in court, certainly not the DHSC/government. They'll push it just far enough.

There's a reason why the good law project are p@ssing their pants over ABDX and a 7.5m payment yet not one mention of NCYT and a far bigger dispute. Our dispute is purely contractual. No brown envelopes etc, we'll have nothing to hide. That much I'll give the CEO credit for.

EKF were making (pre-tax) 5.5m 2019 and 5.8m 2018 on a p/e that averaged around 26 and are now on a p/e of 32. Do people seriously think that we can't better that even with declining covid income over the coming years, with our hugely increased number of distributors, instrument base and contracts. We are being held to a very different standard to every other player in the sector for whatever reason the market has decided to.

They've reiterated the 100m ex DHSC outlook 4 times in the last 1.5 months, if there was any revision down from that I'd expect to see resignations at board level including the chairman. They must be confident of having that in the bag.

The DHSC, Excalibur, UNICEF and WHO had no issues entering into contracts with NCYT post dispute.

200p would value the company at less than likely CAB + inventory right now with nothing for Q4 evermind future earnings beyond. Possible I suppose but at that point it would be an insane valuation, then again it's an insane valuation now.

Read 'em and weep

https://www.bloomberg.com/news/articles/2021-09-30/dna-firm-oxford-nanopore-soars-in-london-trading-debut-after-ipo

Covid over? Look at Kettering. Infection rates over 6000 per 100k in school children, those are 20 times the current UK rate and that's now spilling over into adults. Guaranteed to result in hospitalizations and sadly deaths. Covid isn't done with the UK yet.

https://twitter.com/ProfColinDavis/status/1443253505238736896?s=19

BYP what's the epic for Oxford? I'm in the mood for some self flagellation.

@hillseeker "eat your heart out Oxford Nanopore", indeed.

It would be interesting to know whether the DHSC has done any further business with them since their contract was cancelled in April, I think additionally from a POC point of view our products are not only cheaper but better suited. However, they're the ones getting the all the attention with their IPO and an eye watering Mcap. You've got to hope it drags some value seeking IIs here at this valuation.

The LFTs were a side show, a panic development. The regulatory delays have been known about since at least August, hence why I wasn't happy with the response from Mullis at the Q&A, this disappointment could have been avoided if he'd just fronted up and told it as it was. Other shareholders of companies in the LFT space should take note and NCYT should stick to what it's good at.

Wonder if these regulatory delays will impact the governments decision to switch day 2 testing requirements to LFT because in November you will not be able to sell LFTs that haven't been validated through the process and the testing service providers have already said they will struggle to meet demand. Then we have Biograd significantly dropping the price of PCR to below that of most LFT services in any case.

Coprep is an excellent addition to the Q16/32 range, taking away the labour intensive fluid prep and perhaps the solution to our dispute with the DHSC along with promate. I'd be interested to know if it could be used for non promate products in a cat 2 lab or is it NCYTs intention to make all future near patient products Promate.

Had a look at the difference between an open and closed AGM. Essentially an open AGM allows for interaction between the board and investors at the meeting by way of questions submitted before and during the meeting. The switch from a closed to open AGM is a concession of sorts from the board and perhaps an acknowledgement that all is not well in the relationship and an olive branch offered.

You can submit questions on the online form used to vote on resolutions, the option was available for the originally scheduled AGM.

It's an open virtual meeting, perhaps they'll employ the services of Donkey Kong to keep the cyber mob in check.

On a more serious note, does anyone know the difference between an open and closed meeting in this context?

Someone needs to brush up on their geography.

https://twitter.com/PickardJE/status/1443226972499456008?s=19

From GMs retirement rns:

David's position on the board of Novacyt will be proposed for ratification by shareholders at the Company's 2022 Annual General Meeting.

Hmm, open meeting this time as opposed to the cancelled meeting which was due to be a closed one. Hard to see how DA can head this one as officially he won't have been ratified so is this to be GMs final act?

Then there will never be a more opportune time than at the reconvened AGM for PIs to exert what little influence they can, whichever way they choose to vote.

If they couldn't garner the interest of 20% of their shareholders to vote at an AGM and an EGM to ratify a new CEO and didn't go looking for the reasons why not then you'd seriously have to question their competency to hold the positions they do.

They'll be very much aware, whether they care enough to do something about it or not is a different matter.

I'm not so sure it's promate otherwise why build up a further 16m of inventory at the end of H1, is it not more likely exsig or winterplex.